Drug intelligence / Profile preview

Remedril

Development stage: Unknown
Lead developer: Remed Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

**Remedril** is an oral fixed-dose combination of phenylephrine hydrochloride and brompheniramine maleate marketed by Remed Pharmaceuticals for symptomatic management of upper-respiratory allergic and cold symptoms. Phenylephrine is a direct alpha-1 adrenergic receptor agonist that constricts nasal mucosal blood vessels to reduce congestion, while brompheniramine is a sedating first-generation histamine H1 receptor antagonist that reduces histamine-mediated sneezing, rhinorrhea, itching, and watery eyes. The product is supplied as syrup and oral drops and is indicated for common colds, allergic rhinitis, and sinusitis.

Brand names: Remedril
Other names: brompheniramine maleate + phenylephrine hydrochloridephenylephrine hydrochloride + brompheniramine maleate

Targets

ADRA1A (α1A)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Remedril.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Remedril.

Explore the full profile